



Press Release, April 21, 2021

## **Diamyd Medical to present at Precision Medicine conference**

*CEO Ulf Hannelius has been invited to give a talk at the “Precision medicine – From patient to lab and back again” conference organized by the Copenhagen Bioscience Cluster, a Novo Nordisk foundation initiative.*

The talk, which is based on an abstract submitted to the conference entitled “Developing data-driven precision therapies for Type 1 diabetes”, will focus on how the data collected in Diamyd Medical’s clinical trials together with scientific advances in the field have informed the development of the precision medicine diabetes vaccine Diamyd® for the treatment of type 1 diabetes. The conference will be held digitally May 2<sup>nd</sup> to 6<sup>th</sup>

More information about the conference can be found here: <https://cph-bioscience.com/en/events/cbc21-2may2021>

### **About Diamyd Medical**

Diamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. A new facility for vaccine manufacturing is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser; phone: +46 8-528 00 399, e-mail: [info@fnca.se](mailto:info@fnca.se)

### **For further information, please contact:**

Ulf Hannelius, President and CEO  
Phone: +46 736 35 42 41  
E-mail: [ulf.hannelius@diamyd.com](mailto:ulf.hannelius@diamyd.com)

### **Diamyd Medical AB (publ)**

Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68  
E-mail: [info@diamyd.com](mailto:info@diamyd.com) Reg. no.: 556242-3797 Website: <https://www.diamyd.com>

The information was provided by the contact person above, for publication on April 21, 2021, 12.00 CET.